| Type | Title | Date Released | |
|---|---|---|---|
8-K | Azitra Expands Phase 1/2 Clinical Trial Eligibility for ATR-04 to Include KRAS and MEK Inhibitor Rashes | ||
8-K | Ex vivo studies show ATR-COSF reduced fine lines and improved skin elasticity, with first-in-human results expected by year-end. | ||
8-K | 1-for-10 Reverse Stock Split Takes Effect October 26, With Shares Trading on Split-Adjusted Basis at Market Open | ||
8-K | Azitra Advances ATR-04 Phase 1/2 Clinical Trial to Cohort 2 Following Safety Review Committee Clearance | ||
8-K | Azitra, Inc. Enters into $3.5M At-The-Market Sales Agreement with A.G.P./Alliance Global Partners | ||
424B5 | SUSPENDED September 2026 ATM | Offering amount: $3,503,232 | Bank: A.G.P./Alliance Global Partners | ||
8-K | Azitra, Inc. to Present at the H.C. Wainwright 28th Annual Global Investment Conference | ||
8-K | Azitra, Inc. Regains Compliance with NYSE American Continued Listing Standards | ||
SCHEDULE 13G | Nantahala Capital Management, LLC (Filed by) | ||
SCHEDULE 13G | Nantahala Capital Partners Limited Partnership (Filed by) | ||
8-K | Azitra, Inc. Reports Q2 2026 Financial Results and Business Updates | ||
10-Q | Form 10-Q |
